公开(公告)号：US20170274025A1

公开(公告)日：2017-09-28

申请号：US15616585

申请日：2017-06-07

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Hiroaki Uchida ,  Justus B. Cohen ,  Joseph C. Glorioso, III ,  Paola Grandi

IPC分类号： A61K35/763 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K35/763 ,  C07K14/005 ,  C07K2319/33 ,  C12N7/00 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16641 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2710/16662 ,  C12N2710/16671

摘要： The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.

公开(公告)号：US08927251B2

公开(公告)日：2015-01-06

申请号：US12065455

申请日：2006-08-30

申请人： Guoying Zhou ,  Bernard Roizman

发明人： Guoying Zhou ,  Bernard Roizman

IPC分类号： C12N7/01 ,  C12N15/869 ,  A61K39/245 ,  A61K49/00 ,  A61K47/48 ,  A61K38/20 ,  C12Q1/70

CPC分类号： C07K16/18 ,  A61K35/00 ,  A61K38/2086 ,  A61K47/642 ,  A61K47/6801 ,  A61K47/69 ,  A61K47/6901 ,  C07K14/5437 ,  C12N15/86 ,  C12N15/8695 ,  C12N2710/16632 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2799/028 ,  C12N2810/50 ,  C12N2810/852 ,  C12Q1/705

摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.

摘要翻译： 本发明涉及靶向一种或多种特异性结合对成员（例如受体）的工程化单纯疱疹病毒（HSV）颗粒。 此外，提供了用于生产这种HSV颗粒的重组载体。 通过降低HSV对其天然受体的亲合力并增加对选定受体的亲和力，本发明的HSV颗粒可用于靶向表达所选受体的细胞，其本身可能是遗传工程的产物。 选择性靶向细胞的能力使HSV颗粒。 特别可用于选择性地诊断，治疗和成像携带所选择的结合对成员例如受体的细胞。 本发明还提供了携带选定结合对成员例如受体的细胞的基于多核苷酸的治疗。

公开(公告)号：US07550148B2

公开(公告)日：2009-06-23

申请号：US11215636

申请日：2005-08-30

申请人： Guoying Zhou ,  Bernard Roizman

发明人： Guoying Zhou ,  Bernard Roizman

IPC分类号： A01N63/00 ,  A61K48/00 ,  A61K39/245 ,  C12N7/01

CPC分类号： C12N15/86 ,  A61K47/642 ,  A61K47/6901 ,  A61K48/00 ,  C07K2319/74 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2810/852

摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.

摘要翻译： 本发明涉及靶向一种或多种特异性结合对成员（例如受体）的工程化单纯疱疹病毒（HSV）颗粒。 此外，提供了用于生产这种HSV颗粒的重组载体。 通过降低HSV对其天然受体的亲合力并增加对选定受体的亲和力，本发明的HSV颗粒可用于靶向表达所选受体的细胞，其本身可能是遗传工程的产物。 选择性靶向细胞的能力使得HSV颗粒特别可用于选择性地诊断，治疗和成像携带所选择的结合对成员例如受体的细胞。 本发明还提供了携带选定结合对成员例如受体的细胞的基于多核苷酸的治疗。

公开(公告)号：US06673602B1

公开(公告)日：2004-01-06

申请号：US09592537

申请日：2000-06-12

申请人： Matthew A. Spear ,  Xandra O. Breakefield

发明人： Matthew A. Spear ,  Xandra O. Breakefield

IPC分类号： C12N1500

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2810/40 ,  C12N2810/60

摘要： The present invention relates to herpes simplex virus (HSV) amplicon vectors, and in particular, HSV-1 amplicon vectors, which have been genetically modified and used alone or with consequent genetically modified HSV virus, to target a selected cell type, such as neoplastic cells. The present invention also relates to methods of using such vectors to target a cell, in order to treat a pathologic condition, such as cancer.

摘要翻译： 本发明涉及单纯疱疹病毒（HSV）扩增子载体，特别是HSV-1扩增子载体，其已被遗传修饰并且单独使用或随后使用遗传修饰的HSV病毒靶向所选择的细胞类型，例如肿瘤 细胞。 本发明还涉及使用这些载体靶向细胞的方法，以便治疗诸如癌症的病理状况。